HighTower Advisors
CBAY

HighTower Advisors’s Cymabay Therapeutics CBAY Stock Holding History

HighTower Advisors’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-12,020
Closed -$159K – 2540
2019
Q1 		$159K Hold
12,020
– – ﹤0.01% 2007
2018
Q4 		$94K Buy
+12,020
New +$114K ﹤0.01% 1963

Other funds holding CBAY

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return

HighTower Advisors's CBAY Position: Q2 2019 in Review

HighTower Advisors sold out of Cymabay Therapeutics (CBAY) in Q2 2019, closing a stake of 12,020 shares — an estimated $159K sold.

HighTower Advisors first reported a position in CBAY in Q4 2018 and held it in 2 quarters. The position peaked at $159K in Q1 2019. 133 funds tracked by Wall St. Rank hold CBAY as of Q2 2019.

  • HighTower Advisors reported no remaining Cymabay Therapeutics position as of Q2 2019 after selling out during the quarter.
  • HighTower Advisors sold 12,020 Cymabay Therapeutics shares in Q2 2019, an estimated $159K.
  • HighTower Advisors first reported a position in Cymabay Therapeutics in Q4 2018 and held it in 2 quarters.
  • HighTower Advisors's Cymabay Therapeutics position peaked at $159K in Q1 2019.
  • 133 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q2 2019.

Based on HighTower Advisors's 13F filing for Q2 2019, filed 13 Aug 2019.